The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion
Open accessAbstract
Although the role of PD-L1 in suppressing the anti-tumor immune response is extensively documented, recent discoveries indicate a distinct tumor-intrinsic role for PD-L1 in modulating epithelial-to-mesenchymal transition (EMT), cancer stem cell (CSC)-like phenotype, metastasis and resistance to therapy. In this review, we will focus on the newly discovered functions of PD-L1 in the regulation of cancer development, describe underlying molecular mechanisms responsible for PD-L1 upregulation and discuss current insights into novel components of PD-L1 signaling. Furthermore, we summarize our current understanding of the link between PD-L1 signaling and the EMT program as well as the CSC state. Tumor cell-intrinsic PD-L1 clearly contributes to cancer stemness, EMT, tumor invasion and chemoresistance in multiple tumor types. Conversely, activation of OCT4 signaling and upregulation of EMT inducer ZEB1 induce PD-L1 expression in cancer cells, thereby suggesting a possible immune evasion mechanism employed by cancer stem cells during metastasis. Our meta-analysis demonstrated that PD-L1 is co-amplified along with MYC, SOX2, N-cadherin and SNAI1 in the TCGA endometrial and ovarian cancer datasets. Further identification of immune-independent PD-L1 functions and characterization of crucial signaling events upstream or downstream of PD-L1 in diverse cancer types and specific cancer subtypes, would provide additional targets and new therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942
Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00561 · Cited by 1,707
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
Cancer stem cells as key drivers of tumour progression
Ayob, A. Z., & Ramasamy, T. S. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0426-4 · Cited by 910
Gao, Q., Wang, X.-Y., Qiu, S.-J., Yamato, I., Sho, M., Nakajima, Y., Zhou, J., Li, B.-Z., Shi, Y.-H., Xiao, Y.-S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1608 · Cited by 813
PD-L1 expression in human cancers and its association with clinical outcomes
Yu, J., Wang, X., Teng, F., & Kong, L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105862 · Cited by 787
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen, J., Jiang, C. C., Jin, L., & Zhang, X. D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv615 · Cited by 767
p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs
Chang, C.-J., Chao, C.-H., Xia, W., Yang, J.-Y., Xiong, Y., Li, C.-W., Yu, W.-H., Rehman, S. K., Hsu, J. L., Lee, H.-H., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2173 · Cited by 745
Self-citationPDL1 Regulation by p53 via miR-34
Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv303 · Cited by 683
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Kataoka, K., Shiraishi, Y., Takeda, Y., Sakata, S., Matsumoto, M., Nagano, S., Maeda, T., Nagata, Y., Kitanaka, A., Mizuno, S., et al. (2016) · Nature · doi:10.1038/nature18294 · Cited by 651
Mu, C.-Y., Huang, J.-A., Chen, Y., Chen, C., & Zhang, X.-G. (2011) · Medical Oncology · doi:10.1007/s12032-010-9515-2 · Cited by 577
Lipson, E. J., Vincent, J. G., Loyo, M., Kagohara, L. T., Luber, B. S., Wang, H., Xu, H., Nayar, S. K., Wang, T. S., Sidransky, D., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0034 · Cited by 378
Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment
Renner, K., Singer, K., Koehl, G. E., Geissler, E. K., Peter, K., Siska, P. J., & Kreutz, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00248 · Cited by 374
Interaction of tumor cells with the microenvironment
Ungefroren, H., Sebens, S., Seidl, D., Lehnert, H., & Hass, R. (2011) · Cell Communication and Signaling · doi:10.1186/1478-811x-9-18 · Cited by 333
Wang, X., Yang, L., Huang, F., Zhang, Q., Liu, S., Ma, L., & You, Z. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.02.006 · Cited by 324
Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers
Mezache, L., Paniccia, B., Nyinawabera, A., & Nuovo, G. J. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.108 · Cited by 311
Heeren, A. M., Punt, S., Bleeker, M. C., Gaarenstroom, K. N., van der Velden, J., Kenter, G. G., de Gruijl, T. D., & Jordanova, E. S. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.64 · Cited by 310
The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1
Janse van Rensburg, H. J., Azad, T., Ling, M., Hao, Y., Snetsinger, B., Khanal, P., Minassian, L. M., Graham, C. H., Rauh, M. J., & Yang, X. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3139 · Cited by 306
MethHC: a database of DNA methylation and gene expression in human cancer
Huang, W.-Y., Hsu, S.-D., Huang, H.-Y., Sun, Y.-M., Chou, C.-H., Weng, S.-L., & Huang, H.-D. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1151 · Cited by 296
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
Chen, N., Fang, W., Lin, Z., Peng, P., Wang, J., Zhan, J., Hong, S., Huang, J., Liu, L., Sheng, J., et al. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2005-z · Cited by 288
PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
Böger, C., Behrens, H.-M., Mathiak, M., Krüger, S., Kalthoff, H., & Röcken, C. (2016) · Oncotarget · doi:10.18632/oncotarget.8169 · Cited by 287
Xu, S., Tao, Z., Hai, B., Liang, H., Shi, Y., Wang, T., Song, W., Chen, Y., OuYang, J., Chen, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11406 · Cited by 287
Alsuliman, A., Colak, D., Al-Harazi, O., Fitwi, H., Tulbah, A., Al-Tweigeri, T., Al-Alwan, M., & Ghebeh, H. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0421-2 · Cited by 285
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells
Wu, A. A., Drake, V., Huang, H.-S., Chiu, S., & Zheng, L. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1016700 · Cited by 271
Immune Suppression in the Tumor Microenvironment
Gajewski, T. F., Meng, Y., & Harlin, H. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000199193.29048.56 · Cited by 265
Fujita, Y., Yagishita, S., Hagiwara, K., Yoshioka, Y., Kosaka, N., Takeshita, F., Fujiwara, T., Tsuta, K., Nokihara, H., Tamura, T., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.10 · Cited by 261
MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer
Maeda, T., Hiraki, M., Jin, C., Rajabi, H., Tagde, A., Alam, M., Bouillez, A., Hu, X., Suzuki, Y., Miyo, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1636 · Cited by 250
Almozyan, S., Colak, D., Mansour, F., Alaiya, A., Al‐Harazi, O., Qattan, A., Al‐Mohanna, F., Al‐Alwan, M., & Ghebeh, H. (2017) · International Journal of Cancer · doi:10.1002/ijc.30834 · Cited by 238
The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity
Ostrand-Rosenberg, S., Horn, L. A., & Haile, S. T. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401572 · Cited by 228
The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
Zhao, L., Yu, H., Yi, S., Peng, X., Su, P., Xiao, Z., Liu, R., Tang, A., Li, X., Liu, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9659 · Cited by 226
Lee, Y., Shin, J. H., Longmire, M., Wang, H., Kohrt, H. E., Chang, H. Y., & Sunwoo, J. B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2665 · Cited by 219
The relevance of EMT in breast cancer metastasis: Correlation or causality?
Bill, R., & Christofori, G. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.05.002 · Cited by 192
GENT: Gene Expression Database of Normal and Tumor Tissues
Shin, G., Kang, T.-W., Yang, S., Baek, S.-J., Jeong, Y.-S., & Kim, S.-Y. (2011) · Cancer Informatics · doi:10.4137/cin.s7226 · Cited by 188
Yagi, T., Baba, Y., Ishimoto, T., Iwatsuki, M., Miyamoto, Y., Yoshida, N., Watanabe, M., & Baba, H. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000002616 · Cited by 182
PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
Crane, C. A., Panner, A., Murray, J. C., Wilson, S. P., Xu, H., Chen, L., Simko, J. P., Waldman, F. M., Pieper, R. O., & Parsa, A. T. (2009) · Oncogene · doi:10.1038/onc.2008.384 · Cited by 181
OCT4 promotes tumorigenesis and inhibits apoptosis of cervical cancer cells by miR-125b/BAK1 pathway
Wang, Y.-D., Cai, N., Wu, X.-L., Cao, H.-Z., Xie, L.-L., & Zheng, P.-S. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.272 · Cited by 178
Zhu, J., Chen, L., Zou, L., Yang, P., Wu, R., Mao, Y., Zhou, H., Li, R., Wang, K., Wang, W., et al. (2014) · Human Immunology · doi:10.1016/j.humimm.2014.01.006 · Cited by 171
Kim, S., Koh, J., Kim, M.-Y., Kwon, D., Go, H., Kim, Y. A., Jeon, Y. K., & Chung, D. H. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.07.007 · Cited by 167
Straub, M., Drecoll, E., Pfarr, N., Weichert, W., Langer, R., Hapfelmeier, A., Götz, C., Wolff, K.-D., Kolk, A., & Specht, K. (2016) · Oncotarget · doi:10.18632/oncotarget.7593 · Cited by 161
Okita, R., Maeda, A., Shimizu, K., Nojima, Y., Saisho, S., & Nakata, M. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1986-y · Cited by 159
Kao, S., Cheng, Y. Y., Williams, M., Kirschner, M. B., Madore, J., Lum, T., Sarun, K. H., Linton, A., McCaughan, B. C., Klebe, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.024 · Cited by 152
PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation
Qiu, X. Y., Hu, D. X., Chen, W., Chen, R. Q., Shi, Q., Li, C. Y., Li, Y. J., Xiong, X., Liu, D., Pan, F., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.03.002 · Cited by 152
Yee, D., Shah, K., Coles, M. C., Sharp, T. V., & Lagos, D. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.809053 · Cited by 145
Clinical Significance of B7‐H1 and B7‐1 Expressions in Pancreatic Carcinoma
Wang, L., Ma, Q., Chen, X., Guo, K., Li, J., & Zhang, M. (2010) · World Journal of Surgery · doi:10.1007/s00268-010-0448-x · Cited by 144
B7H3 As a Promoter of Metastasis and Promising Therapeutic Target
Dong, P., Xiong, Y., Yue, J., Hanley, S. J. B., & Watari, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00264 · Cited by 138
Self-citationBarrett, M. T., Anderson, K. S., Lenkiewicz, E., Andreozzi, M., Cunliffe, H. E., Klassen, C. L., Dueck, A. C., McCullough, A. E., Reddy, S., Ramanathan, R. K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4494 · Cited by 135
Dong, P., Xiong, Y., Yu, J., Chen, L., Tang, T., Song, Y., Hanley, S. J. B., Yue, J., Watari, H., & Sakuragi, N. (2018) · Oncogene · doi:10.1038/s41388-018-0347-4 · Cited by 135
Self-citationDong, P., Konno, Y., Watari, H., Hosaka, M., Noguchi, M., & Sakuragi, N. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0231-0 · Cited by 134
Self-citationLiu, C., Lü, J., Tian, H., Du, W., Zhao, L., Feng, J., Yuan, D., & Li, Z. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6102 · Cited by 134
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
Johnson, R. M. G., & Dong, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00961 · Cited by 133
Gene signature driving invasive mucinous adenocarcinoma of the lung
Guo, M., Tomoshige, K., Meister, M. A., Muley, T., Fukazawa, T., Tsuchiya, T., Karns, R. A., Warth, A., Fink-Baldauf, I. M., Nagayasu, T., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606711 · Cited by 128
Tsutsumi, S., Saeki, H., Nakashima, Y., Ito, S., Oki, E., Morita, M., Oda, Y., Okano, S., & Maehara, Y. (2017) · Cancer Science · doi:10.1111/cas.13237 · Cited by 123
Gupta, H. B., Clark, C. A., Yuan, B., Sareddy, G. R., Pandeswara, S., Padron, A. S., Hurez, V. J., Conejo-Garcia, J. R., Vadlamudi, R. K., Li, R., et al. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.30 · Cited by 122
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p
Audrito, V., Serra, S., Stingi, A., Orso, F., Gaudino, F., Bologna, C., Neri, F., Garaffo, G., Nassini, R., Baroni, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15213 · Cited by 119
Liu, S., Chen, S., Yuan, W., Wang, H., Chen, K., Li, D., & Li, D. (2017) · Oncotarget · doi:10.18632/oncotarget.21914 · Cited by 116
PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer
Chen, L., Xiong, Y., Li, J., Zheng, X. W., Zhou, Q., Turner, A., Wu, C., Lu, B., & Jiang, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000480000 · Cited by 115
Self-citationPD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma
Wang, Y., Wang, H., Zhao, Q., Xia, Y., Hu, X., & Guo, J. (2015) · Medical Oncology · doi:10.1007/s12032-015-0655-2 · Cited by 114
Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
George, J., Saito, M., Tsuta, K., Iwakawa, R., Shiraishi, K., Scheel, A. H., Uchida, S., WATANABE, S.-I. I., Nishikawa, R., Noguchi, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1069 · Cited by 108
Yang, W., Lu, Y., Yang, Y., Kang, J., Jin, Y., & Wang, H. (2017) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13411 · Cited by 101
Li, J., Chen, L., Xiong, Y., Zheng, X. W., Xie, Q., Zhou, Q., Shi, L., Wu, C., Jiang, J., & Wang, H. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000460504 · Cited by 99
Self-citationYang, L., Huang, F., Mei, J., Wang, X., Zhang, Q., Wang, H., Xi, M., & You, Z. (2016) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000875 · Cited by 93
STAT1 Drives Tumor Progression in Serous Papillary Endometrial Cancer
Kharma, B., Baba, T., Matsumura, N., Kang, H., Hamanishi, J., Murakami, R., McConechy, M. M., Leung, S. C. Y., Yamaguchi, K. D., Hosoe, Y., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0847 · Cited by 91
Cioffi, M., Trabulo, S. M. D., Vallespinós, M., Raj, D., Kheir, T. B., Lin, M.-L., Begum, J., Baker, A., Amgheib, A., Saif, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15450 · Cited by 90
The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis
Xue, S., Song, G., & Yu, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-04023-x · Cited by 90
B7-H3 promotes gastric cancer cell migration and invasion
Li, Y., Yang, X., Wu, Y., Zhao, K., Ye, Z., Zhu, J., Xu, X., Zhao, X., & Xing, C. (2017) · Oncotarget · doi:10.18632/oncotarget.17847 · Cited by 88
FOXOs in cancer immunity: Knowns and unknowns
Deng, Y., Wang, F., Hughes, T. L., & Yu, J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.005 · Cited by 85
Tumor cell-associated immune checkpoint molecules – Drivers of malignancy and stemness
Marcucci, F., Rumio, C., & Corti, A. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.006 · Cited by 84
Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells
Liao, Y., Chen, L., Feng, Y., Shen, J. K., Gao, Y., Cote, G. M., Choy, E., Harmon, D. C., Mankin, H. J., Hornicek, F. J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16326 · Cited by 81
EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis
Ihira, K., Dong, P., Xiong, Y., Watari, H., Konno, Y., Hanley, S. J. B., Noguchi, M., Hirata, N., Suizu, F., Yamada, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14586 · Cited by 79
Self-citationZhao, L.-W., Li, C., Zhang, R.-L., Xue, H., Fu-xi, Z., Zhang, F., & Gai, X. (2014) · Acta Histochemica · doi:10.1016/j.acthis.2014.06.003 · Cited by 78
MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs
Pyzer, A. R., Stroopinsky, D., Rosenblatt, J. M., Anastasiadou, E., Rajabi, H. N., Washington, A. J., Tagde, A., Chu, J.-H., Coll, M. D., Jiao, A. L., et al. (2017) · Leukemia · doi:10.1038/leu.2017.163 · Cited by 78
Zhi, Y., Mou, Z., Chen, J., He, Y., Dong, H. F., Fu, X., & Wu, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135528 · Cited by 73
Wang, S., Xu, L., Che, X., Li, C., Xu, L., Hou, K., Fan, Y., Wen, T., Qu, X., & Liu, Y. (2018) · FEBS Letters · doi:10.1002/1873-3468.12985 · Cited by 72
Zhong, F., Cheng, X., Sun, S., & Zhou, J. (2017) · Oncology Reports · doi:10.3892/or.2017.5523 · Cited by 70
Holla, S., Victor, E. S., Prakhar, P., Sharma, M., Saha, C., Udupa, V., Kaveri, S. V., Bayry, J., & Balaji, K. N. (2016) · Scientific Reports · doi:10.1038/srep24193 · Cited by 69
MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma
Wang, Y., Wang, D., Xie, G., Yin, Y., Zhao, E., Tao, K., & Li, R. (2017) · Oncotarget · doi:10.18632/oncotarget.15924 · Cited by 69
Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
Zhu, J., Wen, H., Bi, R., Wu, Y., & Wu, X. (2017) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2017.28.e77 · Cited by 62
Prognostic Role of PD-L1 in Malignant Solid Tumors: A Meta-Analysis
Pyo, J., Kang, G., & Kim, J. Y. (2017) · The International Journal of Biological Markers · doi:10.5301/jbm.5000225 · Cited by 61
CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors
Mamessier, É., Birnbaum, D. J., Finetti, P., Birnbaum, D., & Bertucci, F. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.26 · Cited by 57
Zhang, Y., Xiang, C., Wang, Y., Duan, Y., Liu, C., & Zhang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.21328 · Cited by 55
Jinesh, G. G., Manyam, G. C., Mmeje, C., Baggerly, K., & Kamat, A. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-08796-z · Cited by 54
Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression
Saito, H., Kono, Y., Murakami, Y., Shishido, Y., Kuroda, H., Matsunaga, T., Fukumoto, Y., Osaki, T., Ashida, K., & Fujiwara, Y. (2018) · Anticancer Research · doi:10.21873/anticanres.12197 · Cited by 54
Tamai, K., Nakamura, M., Mizuma, M., Mochizuki, M., Yokoyama, M., Endo, H., Yamaguchi, K., Nakagawa, T., Shiina, M., Unno, M., et al. (2014) · Cancer Science · doi:10.1111/cas.12406 · Cited by 49
Budczies, J., Denkert, C., Győrffy, B., Schirmacher, P., & Stenzinger, A. (2017) · BMC Medical Genomics · doi:10.1186/s12920-017-0308-8 · Cited by 45
Wang, Y. F., Liu, F., Sherwin, S. K., Farrelly, M. L., Yan, X. G., Croft, A. J., Liu, T., Jin, L., Zhang, X. D., & Jiang, C. C. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.11.009 · Cited by 41
Nishino, M., Ozaki, M., Hegab, A. E., Hamamoto, J., Kagawa, S., Arai, D., Yasuda, H., Naoki, K., Soejima, K., Saya, H., et al. (2017) · Journal of Cancer · doi:10.7150/jca.19732 · Cited by 39
Expression of immune checkpoint molecules in endometrial carcinoma
Liu, J., Liu, Y., Wang, W., Wang, C., & CHE, Y. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2714 · Cited by 37
TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)
Cao, X. X., Zhao, Y., Wang, J., Dai, B., Gentile, E., Lin, J., Pu, X., Ji, L., Wu, S., Meraz, I. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22581 · Cited by 23
Cited by
Regulation of PD-L1 Expression by NF-κB in Cancer
Antonangeli, F., Natalini, A., Garassino, M. C., Sica, A., Santoni, A., & Di Rosa, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584626 · Cited by 385
Dong, W., Wu, X., Ma, S., Wang, Y., Nalin, A. P., Zhu, Z., Zhang, J., Benson, D. M., He, K., Caligiuri, M. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1259 · Cited by 302
Huang, K.-W., Hsu, F.-F., Qiu, J. T., Chern, G.-J., Lee, Y.-A., Chang, C.-C., Huang, Y.-T., Sung, Y.-C., Chiang, C.-C., Huang, R.-L., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax5032 · Cited by 256
Fang, W., Zhou, T., Shi, H., Yao, M., Zhang, D., Qian, H., Zeng, Q., Wang, Y., Jin, F., Chai, C., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01786-6 · Cited by 256
Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.568931 · Cited by 243
Metadata
- Authors
- Dong, P., Xiong, Y., Yue, J., Hanley, S. J. B., & Watari, H.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2018-09-19
- Volume
- 8
- Pages
- 386-386
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2890371056
- Cited by
- 305
- References
- 98
- FWCI
- 9.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.